MorphoSys Appoints Sung Lee as Chief Monetary Officer

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 6, 2021 / MorphoSys AG (FSE:MOR Prime Standard Segment MDAX & TecDAX NASDAQ:MOR), a commercial-phase biopharmaceutical organization and a chief in antibody, protein and peptide technologies, introduced these days the appointment of Sung Lee as Chief Fiscal Officer, successful February 2, 2021. Mr. Lee succeeds Jens Holstein, who stepped down in December 2020, and will lead all corporate finance features as a member of the Administration Board of MorphoSys AG. He will be primarily based in Planegg, Germany.

Sung Lee

“I am delighted to welcome Sung to MorphoSys while the enterprise executes on its to start with professional launch and is developing by itself as an rising chief in hematology-oncology and autoimmune conditions,” reported Marc Cluzel, M.D., Ph.D., Chairman of the MorphoSys Supervisory Board. “Sung will provide a wealth of practical experience to the Administration Board dependent on his superb keep track of document in scaling companies and leading finance and investor relations features in the U.S. and Europe.”

Jean-Paul Kress, M.D., Main Government Officer of MorphoSys, added: “Throughout his profession, Sung has demonstrated incredible talent in driving fiscal general performance and serving as a strategic assumed spouse. We are confident that Sung’s transformative frame of mind will be instrumental in executing our formidable growth tactic and the accelerated improvement of our pipeline for the advantage of individuals.”

“I am thrilled to be a part of MorphoSys and come to be portion of a workforce that has established its capability to make a actual variation for folks struggling from most cancers,” said Sung Lee. “MorphoSys is a primary illustration of an R&D-targeted company that has successfully progressed into a professional-phase organization, and I am incredibly enthusiastic to assist shape its upcoming progress.”

Sung Lee has additional than 20 several years of finance management experience in biopharmaceutical and technology companies. Mr. Lee joins MorphoSys from Sangamo Therapeutics, Inc., exactly where he served as Main Economic Officer. Prior to that part, Mr. Lee put in just about 14 several years at Gilead Sciences where by he most a short while ago led the international Financial Preparing & Examination and Trader Relations functions.

Mr. Lee started out his vocation in the tax advisory company at PriceWaterhouseCoopers LLP. He gained a Master of Business enterprise Taxation from the College of Southern California and a B.A. in Economics from the University of California, Irvine.

About MorphoSys

MorphoSys is a business-stage biopharmaceutical corporation committed to the discovery, growth and commercialization of innovative therapies for individuals suffering from most cancers and autoimmune diseases. Dependent on its main know-how in antibody, protein and peptide technologies, MorphoSys, collectively with its companions, has made and contributed to the improvement of additional than 100 product candidates, of which 27 are at present in clinical enhancement. In 2017, Tremfya®, made by Janssen Exploration & Enhancement, LLC and marketed by Janssen Biotech, Inc., for the cure of plaque psoriasis, grew to become the very first drug dependent on MorphoSys’ antibody technologies to acquire regulatory acceptance. In July 2020, the U.S. Foods and Drug Administration (Fda) granted accelerated acceptance of the company’s proprietary merchandise Monjuvi® (tafasitamab-cxix) in mix with lenalidomide in clients with a specified variety of lymphoma.

Headquartered close to Munich, Germany, the MorphoSys team, including the entirely owned U.S. subsidiary MorphoSys US Inc., has far more than 600 workforce. More data at www.morphosys.com or www.morphosys-us.com.

Monjuvi® and HuCAL® are registered logos of MorphoSys AG.

Tremfya® is a registered trademark of Janssen Biotech, Inc.

MorphoSys Forward-Looking Statements

This interaction includes particular ahead-wanting statements about the MorphoSys group of corporations, which include the expectations pertaining to Monjuvi’s skill to handle clients with relapsed or refractory diffuse substantial B-mobile lymphoma, the even further clinical improvement of tafasitamab-cxix, together with ongoing confirmatory trials, supplemental interactions with regulatory authorities and anticipations pertaining to long run regulatory filings and doable more approvals for tafasitamab-cxix as well as the commercial general performance of Monjuvi. The terms “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “would,” “could,” “potential,” “possible,” “hope” and comparable expressions are meant to determine forward-searching statements, though not all ahead-seeking statements include these figuring out text. The forward-searching statements contained herein signify the judgment of MorphoSys as of the date of this launch and contain recognized and unfamiliar risks and uncertainties, which may possibly induce the genuine success, economic situation and liquidity, functionality or achievements of MorphoSys, or business benefits, to be materially distinctive from any historic or upcoming outcomes, economical situations and liquidity, general performance or achievements expressed or implied by these kinds of ahead-looking statements. In addition, even if MorphoSys’ outcomes, overall performance, financial affliction and liquidity, and the progress of the business in which it operates are steady with these kinds of forward-wanting statements, they may well not be predictive of success or developments in long term durations. Amongst the variables that may perhaps consequence in variances are MorphoSys’ anticipations relating to hazards and uncertainties linked to the impression of the COVID-19 pandemic to MorphoSys’ small business, functions, strategy, goals and anticipated milestones, together with its ongoing and prepared investigate actions, capacity to carry out ongoing and prepared medical trials, clinical offer of present or future drug candidates, industrial supply of existing or potential approved merchandise, and launching, marketing and marketing present or potential permitted products, the world wide collaboration and license settlement for tafasitamab, the additional medical development of tafasitamab, together with ongoing confirmatory trials, and MorphoSys’ ability to receive and sustain requisite regulatory approvals and to enroll individuals in its prepared clinical trials, more interactions with regulatory authorities and expectations regarding upcoming regulatory filings and achievable more approvals for tafasitamab-cxix as effectively as the business effectiveness of Monjuvi, MorphoSys’ reliance on collaborations with 3rd parties, estimating the professional probable of its advancement plans and other threats indicated in the possibility variables incorporated in MorphoSys’ Once-a-year Report on Type 20-F and other filings with the U.S. Securities and Trade Fee. Given these uncertainties, the reader is suggested not to put any undue reliance on these forward-looking statements. These ahead-looking statements talk only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any this sort of forward-searching statements in this doc to mirror any improve in its anticipations with regard thereto or any modify in situations, conditions or situation on which any these types of assertion is centered or that may possibly impact the likelihood that actual effects will vary from those established forth in the ahead-looking statements, except if exclusively needed by regulation or regulation.

For additional information, you should contact:

Resource: MorphoSys AG

Check out resource model on accesswire.com:

https://www.accesswire.com/623292/MorphoSys-Appoints-Sung-Lee-as-Chief-Economical-Officer